Toggle Main Menu Toggle Search

Open Access padlockePrints

Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transciption 1 (STAT1) mutation

Lookup NU author(s): Tariq AlShehri, Dr Desa Lilic


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


We demonstrate clinical utility of ruxolitinib, a JAK1/2 inhibitor, in CMC due to STAT1 gain-of-function mutation. We show functional data to explain this effect. This drug is a potentially a transformative therapy for these patients.

Publication metadata

Author(s): Higgins E, AlShehri T, McLeer MA, Feighery C, Lilic D, Irvine AD

Publication type: Article

Publication status: Published

Journal: Journal of Allergy and Clinical Immunology

Year: 2015

Volume: 135

Issue: 2

Pages: 551-553

Print publication date: 04/02/2015

Online publication date: 04/02/2015

Acceptance date: 02/02/2015

ISSN (print): 0091-6749

ISSN (electronic): 1097-6825

Publisher: Elsevier


DOI: 10.1016/j.jaci.2014.12.1867


Altmetrics provided by Altmetric